8 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $80M | -$5M | 53.5% | -1.1% | $10M | $31M | $26M |
| 2024 | $39M | -$4M | 60.0% | -6.7% | $943000 | $30M | $15M |
| 2023 | $32M | -$936000 | 66.6% | -3.8% | $7M | $0 | $21M |
| 2022 | $21M | -$9M | 67.4% | -38.9% | $5M | $5M | $16M |
| 2021 | $22M | -$2M | 87.1% | -6.8% | -$5M | $5M | $14M |
| 2020 | $39000 | -$28M | -1017.9% | -69515.4% | -$22M | $7M | $21M |
| 2019 | $959000 | -$18M | 52.8% | -1939.6% | -$19M | $5M | $12M |
| 2018 | — | -$13M | — | — | -$8M | — | $27M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $24M | $2M | 60.7% | 9.9% | $7M | $19M | $20M |
| Dec '25 | $21M | $1M | 61.6% | 11.6% | -$12M | $31M | $26M |
| Sep '25 | $22M | -$2M | 35.0% | -6.1% | $12M | $28M | $37M |
| Jun '25 | $19M | -$3M | 63.0% | -7.8% | $8M | $27M | $25M |
| Mar '25 | $17M | -$2M | 57.1% | -2.7% | $2M | $30M | $17M |
| Dec '24 | $12M | -$598000 | 55.6% | 5.4% | -$777000 | $30M | $15M |
| Sep '24 | $10M | $627000 | 61.0% | 4.9% | $3M | — | $20M |
| Jun '24 | $9M | -$3M | 62.0% | -32.3% | $1M | — | $18M |
| Mar '24 | $8M | -$811000 | 62.9% | -10.0% | -$2M | — | $17M |
| Dec '23 | $7M | -$2M | 49.6% | -27.3% | $387000 | $0 | $21M |
| Sep '23 | $7M | -$579000 | 62.6% | -7.8% | $873000 | $4M | $22M |
| Jun '23 | $12M | $5M | 80.7% | 32.4% | $7M | $5M | $22M |
| Mar '23 | $5M | -$3M | 63.1% | -47.8% | -$2M | $5M | $15M |
| Dec '22 | $8M | $912000 | 74.8% | 12.5% | $3M | $5M | $16M |
| Sep '22 | $3M | -$3M | 62.7% | -89.9% | -$2M | $6M | $13M |
| Jun '22 | $7M | -$2M | 62.7% | -18.2% | $2M | $6M | $17M |
| Mar '22 | $2M | -$5M | 61.0% | -233.8% | $1M | $6M | $15M |
| Dec '21 | $6M | $1M | 93.9% | 21.6% | -$5M | $5M | $14M |
| Sep '21 | $775000 | -$6M | 15.6% | -754.5% | -$3M | $6M | $23M |
| Jun '21 | $3M | -$2M | 94.3% | -75.8% | — | $6M | $26M |
How the market has priced ETON against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Eton Pharmaceuticals, Inc.'s revenue has grown 359.6% per year. These are computed facts, not advice.
As of FY2025, Eton Pharmaceuticals, Inc. reported $31M of total debt against $26M of cash.
In FY2025, gross margin was 53.5%, operating margin -1.1%, and net margin -5.8%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.